Regeneron's Inmazeb Overcame FDA Combo Product Requirements With Nonclinical Evidence

 
• By Sue Sutter
  
Three gears
Using a combination of three mABs is likely to reduce the chance that Inmazeb's efficacy will be impacted by resistance. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews